Masimo Showcases Advanced, Noninvasive Patient Monitoring Technologies at Arab Health

Masimo Showcases Advanced, Noninvasive Patient Monitoring Technologies at Arab
                                    Health

  PR Newswire

  IRVINE, California, Jan. 28, 2013

- Visit Hall 1 U.S. Pavilion, Booth E39, to See Tomorrow's Medical Technology
Today

IRVINE, California, Jan. 28, 2013 /PRNewswire/ -- Masimo (NASDAQ: MASI)
returns to Arab Health Jan. 28-31, the world's longest running healthcare
exhibition and congress held each year in Dubai, UAE, to showcase advanced,
noninvasive patient monitoring technologies – including breakthrough SET®
Measure-Through Motion pulse oximetry and rainbow® Pulse CO-Oximetry® – that
are becoming the standard-of-care across the Middle East.

Masimo will demonstrate more than a half-dozen handheld, mobile, OR, ICU,
NICU, and bedside technologies. Leading-edge Masimo medical devices on display
at Arab Health include:

Radical-7® The 2012 Radical-7® empowers clinicians to improve patient outcomes
and reduce the cost of care in multiple ways, such as reducing blood
transfusion-related costs and detecting bleeding earlier with noninvasive
total hemoglobin (SpHb®), optimizing fluid management with Pleth Variability
Index (PVI®), and enabling reliable detection of respiratory depression with
acoustic respiration rate (RRa™).

(Photo: http://photos.prnewswire.com/prnh/20120326/LA76174-c )

Masimo rainbow® technology allows clinicians to noninvasively measure multiple
blood, fluid, and ventilation parameters that previously required invasive or
complicated procedures, including SpHb®, oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), PVI®, and RRa™, along with
Masimo SET® Measure-Through Motion and low perfusion pulse oximetry for oxygen
saturation (SpO2), pulse rate, and perfusion index (PI). With touch, drag, and
drop functionality, clinicians can move, expand, or collapse any parameter on
screen for real-time analysis. Standard wireless connectivity in the handheld
Radical-7® keeps patients connected even when moving from the OR, to critical
care areas, to the general floor.

Masimo Patient SafetyNet™ The Masimo Patient SafetyNet™ remote monitoring and
clinician notification system combines Masimo rainbow® Pulse CO-Oximetry™ and
rainbow® Acoustic Monitoring™ with wireless clinician notifications via pager
or smartphone – providing an unmatched level of safety for up to 80 patients
on four floors. Patient SafetyNet facilitates early clinical response to
preempt sentinel events and avoid unnecessary ICU transfers while helping meet
The Joint Commission and Anesthesia Patient Safety Foundation guidelines for
patient safety.(1)

(Photo: http://photos.prnewswire.com/prnh/20110912/LA64995 )

SpfO2™ SpfO2™ is a new fractional arterial oxygen saturation parameter through
the rainbow® Universal ReSposable SuperSensor™, the first noninvasive sensor
to provide simultaneous monitoring of SpHb®, SpCO®, SpMet®, SpfO2 ™ , SpOC™,
Perfusion Index, PVI®, and Measure-Through Motion and Low Perfusion SpO2 and
pulse rate. Until now, pulse oximeters could only measure and display
functional oxygen saturation (SpO2), so when patients had elevated
carboxyhemoglobin (from carbon monoxide poisoning) and/or elevated
methemoglobin (negative reaction to more than 30 common drugs used in
hospitals) the displayed functional oxygen saturation overestimated the actual
oxygen saturation value. SpfO2 ™ allows more precise arterial oxygenation
assessment and may allow earlier interventions and more timely therapeutic
decisions. SpfO2™ is pending U.S. FDA 510(k) clearance.

(Photo: http://photos.prnewswire.com/prnh/20130127/LA48858 )

Sneak Previews: Also at the Masimo Booth, we will greet visitors with
sneak-previews of new technologies for patient care.

Masimo Pronto-7® Masimo Pronto-7 ® is a palm-sized handheld device designed
for quick and easy noninvasive spot-checking of hemoglobin (SpHb®), SpO2,
pulse rate, and perfusion index at the point-of-care. Offering a breakthrough
new solution for measuring hemoglobin in less than one minute – without
needles, time-consuming laboratory analysis, blood contamination, hazardous
medical waste, and patient discomfort associated with traditional blood tests
– the Pronto-7 ® puts the power of noninvasive hemoglobin spot-check
measurements into clinician's hands. With dimensions of just 13 cm x 7.2 cm x
2.5 cm (5.1" x 2.8" x 1") and weight of 296 grams (10.5 ounces), Pronto-7 ®
offers the convenience, speed, and accuracy today's care providers need to
facilitate timely assessment and treatment decisions. And embedded 802.11 b/g
and Bluetooth communication capabilities make wireless printing and emailing
of test results quick and easy.

(Photo: http://photos.prnewswire.com/prnh/20110831/LA59123 )

"We are honored to showcase and demonstrate our latest cutting-edge,
noninvasive patient monitoring innovations at Arab Health," said Masimo
founder and CEO Joe Kiani. "As an increasing number of prestigious hospitals
throughout the Middle East adopt Masimo SET® pulse oximetry and rainbow® Pulse
CO-Oximetry, we are pleased to deliver our finest patient monitoring
technology to this vital area of the world."

(1) Taenzer, Andreas H.; Pyke, Joshua B.; McGrath, Susan P.; Blike, George T.
"Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care
Unit Transfers: A Before-and-After Concurrence Study." Anesthesiology ,
February 2010, Vol. 112, Issue 2. Available online here

About Masimo Masimo (NASDAQ: MASI) is the global leader in innovative
noninvasive monitoring technologies that significantly improve patient
care—helping solve "unsolvable" problems. In 1995, the company debuted
Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®,
which virtually eliminated false alarms and increased pulse oximetry's ability
to help clinicians detect life-threatening events. More than 100 independent
and objective studies have shown that Masimo SET® outperforms other pulse
oximetry technologies, even under the most challenging clinical conditions,
including patient motion and low peripheral perfusion. In 2005, Masimo
introduced rainbow SET® Pulse CO-Oximetry technology, allowing noninvasive and
continuous monitoring of blood constituents that previously required invasive
procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index
(PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In 2008,
Masimo introduced Patient SafetyNet™, a remote monitoring and wireless
clinician notification system designed to help hospitals avoid preventable
deaths and injuries associated with failure to rescue events. In 2009, Masimo
introduced rainbow® Acoustic Monitoring™, the first-ever noninvasive and
continuous monitoring of acoustic respiration rate (RRa™). Masimo's rainbow®
SET® technology platform offers a breakthrough in patient safety by helping
clinicians detect life-threatening conditions and helping guide treatment
options. In 2010, Masimo acquired SedLine®, a pioneer in the development of
innovative brain function monitoring technology and devices. In 2012, Masimo
acquired assets of Spire Semiconductor, LLC, maker of advanced light emitting
diode (LED) and other advanced component-level technologies; and Phasein AB, a
developer and manufacturer of ultra-compact mainstream and sidestream
capnography, multigas analyzers, and handheld capnometry solutions. Masimo
SET® and Masimo rainbow® SET® technologies also can be found in over 100
multiparameter patient monitors from over 50 medical device manufacturers
around the world. Founded in 1989, Masimo has the mission of "Improving
Patient Outcome and Reducing Cost of Care ... by Taking Noninvasive Monitoring
to New Sites and Applications®." Additional information about Masimo and its
products may be found at www.masimo.com .

Forward-Looking Statements This press release includes forward-looking
statements as defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking statements are
based on current expectations about future events affecting us and are subject
to risks and uncertainties, all of which are difficult to predict and many of
which are beyond our control and could cause our actual results to differ
materially and adversely from those expressed in our forward-looking
statements as a result of various risk factors including: risks related to our
assumptions regarding the repeatability of clinical results, risks related to
our assumptions that Masimo SpHb accurately tracks and trends Hb changes in
all patients, risks related to our assumptions that Masimo Patient SafetyNet
helps hospitals avoid preventable deaths and injuries associated with failure
to rescue events for all monitored patients, risks related to SpfO2 ™ and
SuperSensors represent an innovative solution to more accurately measure blood
oxygenation and hemoglobin, which could allow clinicians to make earlier
interventions or better therapeutic decisions, risks related to our belief
that the Pronto-7 enables quick and easy noninvasive spot-checking of
hemoglobin (SpHb®), SpO2, pulse rate, and perfusion index at the point-of-care
for all patients, as well as other factors discussed in the "Risk Factors"
section of our most recent reports filed with the Securities and Exchange
Commission (" SEC "), which may be obtained for free at the SEC's website at
www.sec.gov . Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included in
this press release are expressly qualified in their entirety by the foregoing
cautionary statements. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of today's date. We do not
undertake any obligation to update, amend or clarify these statements or the
"Risk Factors" contained in our most recent reports filed with the SEC,
whether as a result of new information, future events or otherwise, except as
may be required under the applicable securities laws.

Media Contact: Mike DrummondMasimo Corporation Phone: (949) 297-7434 Email:
mdrummond@masimo.com

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and
Reducing Cost of Care… by Taking Noninvasive Monitoring to New Sites and
Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic
Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry,
Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine are trademarks or
registered trademarks of Masimo Corporation. The use of the trademarks Patient
SafetyNet and PSN are under license from University HealthSystem Consortium.

Website: hhttp://www.masimo.com
 
Press spacebar to pause and continue. Press esc to stop.